Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 12/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | BPTF | Q12830 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | S100A4 | P26447 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6956277 | 0.98 | ACHE (0.40) | ACHEKMT2AMEN1MAPK1BPTF | |
| SCHEMBL6953068 | 0.72 | ACHE (0.33) | ACHE | |
| SCHEMBL28554918 | 0.70 | ESR1 (0.37) | — | |
| SCHEMBL29606655 | 0.69 | MAPK1 (0.41) | ACHEKMT2AMEN1MAPK1BPTF | |
| SCHEMBL7984326 | 0.69 | ACHE (0.32) | ACHE | |
| SCHEMBL20681024 | 0.67 | GRIN2D (0.37) | KMT2AMEN1KDM4EALDH1A1S100A4 | |
| SCHEMBL3728736 | 0.67 | ACHE (0.39) | ACHEKMT2AMEN1MAPK1BPTF | |
| SCHEMBL7910360 | 0.66 | PRNP (0.42) | ACHEKMT2AMEN1MAPK1BCHE | |
| SCHEMBL15872863 | 0.64 | GPR35 (0.36) | ACHEKMT2AMEN1MAPK1CYP1A2 | |
| SCHEMBL7012946 | 0.64 | USP2 (0.48) | KMT2AMEN1USP2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114364677-B | Imidazo [4,5-C ] pyridine derivatives as TOLL-like receptor agonists | 辉瑞公司 | 2024-07-09 | — | — | CN | disclosed |
| US-11976064-B2 | Toll-like receptor agonists | PFIZER INC. (US) | 2024-05-07 | — | — | US | disclosed |
| US-20220274986-A1 | TOLL-LIKE RECEPTOR AGONISTS | PFIZER INC. (US) | 2022-09-01 | — | — | US | disclosed |
| EP-3999507-A1 | IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS TOLL-LIKE RECEPTOR AGONISTS | Pfizer Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
| US-11339159-B2 | Toll-like receptor agonists | PFIZER INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-11339159-B2 | Toll-like receptor agonists | PFIZER INC. (US) | 2022-05-24 | — | — | US | disclosed |
| CN-114364677-A | Imidazo [4,5-C ] pyridine derivatives as TOLL-like receptor agonists | 辉瑞公司 | 2022-04-15 | — | — | CN | disclosed |
| WO-2021009676-A1 | IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS TOLL-LIKE RECEPTOR AGONSITS | PFIZER INC. (US) | 2021-01-21 | — | — | WO | disclosed |
| WO-2021009676-A1 | IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS TOLL-LIKE RECEPTOR AGONSITS | PFIZER INC. (US) | 2021-01-21 | — | — | WO | disclosed |
| US-20210017172-A1 | TOLL-LIKE RECEPTOR AGONISTS | PFIZER INC. (US) | 2021-01-21 | — | — | US | disclosed |
| US-20210017172-A1 | TOLL-LIKE RECEPTOR AGONISTS | PFIZER INC. (US) | 2021-01-21 | — | — | US | disclosed |
| US-7276515-B2 | Thioether substituted imidazoquinolines | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2007-10-02 | — | — | US | disclosed |
| US-20040072858-A1 | Heterocyclic ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-04-15 | — | — | US | disclosed |
| US-6664260-B2 | Viricides; anticarcinogneic agents; induction cytokine biosynthesis | 3M INNOVATIVE PROPERTIES COMPANY | 2003-12-16 | — | — | US | disclosed |
| EP-1339715-A2 | HETEROCYCLIC ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2003-09-03 | — | — | EP | disclosed |
| US-20030065005-A1 | Heterocyclic ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-04-03 | — | — | US | disclosed |
| WO-2002046193-A2 | HETEROCYCLIC ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065005-A1 | Heterocyclic ether substituted imidazoquinolines | IFNG, IL2, IRF3 | ACHE 4670/4885KMT2A 808/4885MEN1 2581/4885 |
| US-11976064-B2 | Toll-like receptor agonists | TLR3, TLR1, TLR4 | ACHE 4885/4885KMT2A 2354/4885MEN1 3828/4885 |
| US-20210017172-A1 | TOLL-LIKE RECEPTOR AGONISTS | TLR3, TLR1, TLR4 | ACHE 4885/4885KMT2A 2354/4885MEN1 3828/4885 |
| US-11339159-B2 | Toll-like receptor agonists | TLR3, TLR1, TLR4 | ACHE 4885/4885KMT2A 2354/4885MEN1 3828/4885 |
| US-20220274986-A1 | TOLL-LIKE RECEPTOR AGONISTS | TLR3, TLR1, TLR4 | ACHE 4885/4885KMT2A 2354/4885MEN1 3828/4885 |
| US-20040072858-A1 | Heterocyclic ether substituted imidazoquinolines | IFNG, IL2, IRF3 | ACHE 4670/4885KMT2A 808/4885MEN1 2581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.